Prescribing of extended release buprenorphine injection for Medicaid beneficiaries, 2018–2022

Abstract

AbstractBackground and aimsExtended release buprenorphine injection (INJ‐BUP) has been available in the United States since 2018. INJ‐BUP has the potential to positively impact opioid use disorder (OUD) treatment outcomes by providing additional treatment options . As one of the largest payers of OUD treatment in the US, Medicaid coverage is important for access and uptake of INJ‐BUP. Uptake of INJ‐BUP among Medicaid beneficiaries has not been described since 2019 and variation in uptake by state has not previously been explored. We aimed to measure prescribing of INJ‐BUP for Medicaid beneficiaries since 2018, nationwide and by state.MethodsWe analyzed State Drug Utilization Data from 2017 to 2022 and calculated the number of prescription fills for INJ‐BUP and oral buprenorphine paid by Medicaid. To compare across states, we calculated the number of prescription fills per 100 Medicaid beneficiaries treated for OUD using data from Transformed Medicaid Statistical Information System Substance Use Disorder (T‐MSIS SUD) Data Books. Data sources are publicly available.ResultsThe number of prescription fills for INJ‐BUP paid by Medicaid increased from 4322 (0.1% of all buprenorphine prescription fills) in 2018 to 186 861 (2.0%) in 2022. Each year the increase in fills exceeded the prior year change, indicating accelerating uptake. There was notable variability across states.ConclusionsThe number of extended release buprenorphine injection prescriptions among US Medicaid beneficiaries treated for opioid use disorder increased from over 4000 prescriptions in 2018 to over 185 000 in 2022 but uptake is much less than observed in other countries over shorter time periods.